HOWL
insider transactionsWerewolf Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-531.4K
0 buy · 531.4K sell
Net value · 30d
-$233.3K
$0 in · $233.3K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
11
0 buy · 531.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$28.5K
76.9K sh · $0.37
Own -20%
-
Sell·S
Director · 10b5-1
$24.2K
60.5K sh · $0.40
Own -14%
-
Sell·S
Director · 10b5-1
$10.0K
24.9K sh · $0.40
Own -5%
-
Sell·S
Director · 10b5-1
$8.8K
20.1K sh · $0.44
Own -4%
-
Sell·S
Director · 10b5-1
$12.5K
29.7K sh · $0.42
Own -6%
-
Sell·S
Director · 10b5-1
$13.3K
29.6K sh · $0.45
Own -5%
-
Sell·S
Director · 10b5-1
$37.8K
80.5K sh · $0.47
Own -13%
-
Sell·S
Director · 10b5-1
$14.7K
32.6K sh · $0.45
Own -5%
-
Sell·S
Director · 10b5-1
$12.7K
27.7K sh · $0.46
Own -4%
-
Sell·S
Director · 10b5-1
$38.8K
80.9K sh · $0.48
Own -11%
-
Sell·S
Director · 10b5-1
$31.9K
68.0K sh · $0.47
Own -8%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2026 | Luke Evnin 10b5-1 | Sell S | 76.9K | $28.5K |
| Jun 8, 2026 | Luke Evnin 10b5-1 | Sell S | 60.5K | $24.2K |
| Jun 5, 2026 | Luke Evnin 10b5-1 | Sell S | 24.9K | $10.0K |
| Jun 4, 2026 | Luke Evnin 10b5-1 | Sell S | 20.1K | $8.8K |
| Jun 3, 2026 | Luke Evnin 10b5-1 | Sell S | 29.7K | $12.5K |
| Jun 2, 2026 | Luke Evnin 10b5-1 | Sell S | 29.6K | $13.3K |
| Jun 1, 2026 | Luke Evnin 10b5-1 | Sell S | 80.5K | $37.8K |
| May 29, 2026 | Luke Evnin 10b5-1 | Sell S | 32.6K | $14.7K |
| May 28, 2026 | Luke Evnin 10b5-1 | Sell S | 27.7K | $12.7K |
| May 27, 2026 | Luke Evnin 10b5-1 | Sell S | 80.9K | $38.8K |
| May 26, 2026 | Luke Evnin 10b5-1 | Sell S | 68.0K | $31.9K |
About HOWL insider trading
This page tracks insider transactions for Werewolf Therapeutics, Inc. (HOWL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.